Castle Biosciences received approval from the New York State Department of Health for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy for patients aged 12 and older with moderate-to-severe atopic dermatitis. This test helps clinicians select the most effective treatment by analyzing a patient's disease biology from a skin sample, improving personalized care and potentially reducing ineffective treatment cycles. The approval expands access to this precision medicine tool in New York, supporting better outcomes for millions affected by this chronic skin condition. Castle now holds NY approval for all tests in its dermatology and ophthalmology portfolios, enhancing its diagnostic reach.
PayPal's board has reportedly rejected an offer valuing the company at $60.50 per share, considering it inadequate. This comes as PayPal's stock currently trades at around $56 per share. The board's stance suggests they believe the company's value is...
Morgan Stanley's Bitcoin Trust surpassed $400 million in inflows, signaling strong institutional interest amid $51.83 billion cumulative inflows in U.S. Spot Bitcoin ETFs. However, daily ETF outflows of about $240 million and Bitcoin trading below $6...
Shiba Inu lead ambassador Shytoshi Kusama has been silent on social media platform X for 74 days, a pattern seen before during which he focuses on development projects like an independent AI initiative. His silence has left the SHIB community to rely...
Coinbase is proactively upgrading its security systems to protect Bitcoin and other cryptocurrencies from future quantum computing risks. The company is enhancing its proprietary key management system, PQ-CoreKMS, which currently secures 99.9% of its...
U.S. spot Bitcoin ETFs have grown to about $180 billion in assets by 2026, with holdings peaking near 1.38 million BTC and stabilizing around 1.2 million BTC despite Bitcoin trading between $115,000 and $125,000. These ETFs have enabled Wall Street i...
